ACTG 260: A Randomized, Phase I-Ii, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy
Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.43.6.1373
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 1999
Authors
Publisher
American Society for Microbiology